Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04069936 |
Recruitment Status :
Active, not recruiting
First Posted : August 28, 2019
Last Update Posted : June 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Small Cell Lung Cancer Lung Cancer Lung Cancer Metastatic Lung Cancer, Non-small Cell Non Small Cell Lung Cancer Metastatic NSCLC Non-small Cell Lung Cancer Non-small Cell Lung Cancer Metastatic | Biological: MILs™ - NSCLC Biological: nivolumab Drug: tadalafil | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 19 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | In Part 1, approximately 3-6 subjects will be treated with MILs™ - NSCLC alone. Following Part 1, approximately 20 subjects will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Subjects With Locally Advanced and Unresectable or Metastatic NSCLC Previously Treated With Anti-PD-1 |
Actual Study Start Date : | October 15, 2019 |
Estimated Primary Completion Date : | August 2022 |
Estimated Study Completion Date : | March 2027 |

Arm | Intervention/treatment |
---|---|
Experimental: MILs™ - NSCLC plus nivolumab with or without tadalafil
Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.
|
Biological: MILs™ - NSCLC
To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
Other Name: Marrow Infiltrating Lymphocytes Biological: nivolumab To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC Drug: tadalafil To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC |
- Adverse Events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5.0 [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Incidence, intensity, and type of AE
- Serious Adverse Events per NCI-CTCAE version 5.0 [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Incidence, intensity, and type of SAE
- Overall Response Rate (ORR) of MILs™ - NSCLC in combination with nivolumab with or without tadalafil [ Time Frame: 24 months ]Proportion of subjects with reduction in tumor burden of a predefined amount per RECIST 1.1
- Duration of response [ Time Frame: up to 5 years after treatment discontinuation ]Duration from first documented evidence of CR or PR until the first documented evidence of PD or death due to any cause, whichever occurs first
- Disease control rate [ Time Frame: up to 5 years after treatment discontinuation ]Proportion of subjects in the efficacy population who achieve an Investigator-assessed confirmed CR, PR, or SD per RECIST 1.1
- Progression-free survival [ Time Frame: up to 5 years after treatment discontinuation ]Date of first the administration of MILs™ - NSCLC until documented PD or death due to any cause, whichever occurs first
- Overall survival [ Time Frame: up to 5 years after treatment discontinuation ]Duration from the date of administration of MILs™ - NSCLC until death due to any cause
- Overall Response Rate (ORR) of MILs™ - NSCLC [ Time Frame: 24 months ]Proportion of subjects with reduction in tumor burden of a predefined amount per RECIST 1.1
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by vital signs (pulse rate) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Pulse rate in beats/minute
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by vital signs (weight) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Weight in pounds
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by vital signs (blood pressure) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Systolic and diastolic blood pressure in mmHg
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by vital signs (respiratory rate) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Respiratory rate in breaths/minute
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by vital signs (temperature) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Termperature in Fahrenheit
- Safety of MILs™ - NSCLC alone and in combination with nivo. with or w/o tadalafil by liver function (ALT/AST (U/L), albumin (g/dL), tot. bilirubin (mg/dL)), kidney function (creatinine (mg/dL) and endocrine function (T3 free and T4 free (ng/dL)) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Clinical chemistry results will be summarized and changes from baseline provided
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil by cell count (e.g. RBC (10^6/uL), WBC (10^3/uL), absolute cell count (10^3/uL), Hct (%) and Hgb (g/dL) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Hematology results will be summarized and changes from baseline provided
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by APTT (seconds), fibrinogen (mg/dL), INR and protime (seconds) [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Coagulation results will be summarized in data listings
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil as assessed by urine appearance, color, pH, specific gravity and presence of blood, bilirubin, glucose, ketone, leukocyte esterase, nitrite, protein, urobilinogen [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Urinalysis results will be summarized in data listings
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil by electrocardiograms (ECGs) assessed by Investigators as normal, abnormal clinically significant or abnormal not clinically significant [ Time Frame: From ICF through 100 days after the last dose of study treatment ]ECGs results will be summarized and changes from baseline provided
- Safety of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil by physical examination with abnormalities reported as adverse events [ Time Frame: From ICF through 100 days after the last dose of study treatment ]Physical examinations will be performed by the Investigators and any new clinically significant or changes in medical conditions will be reported as adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
- Locally advanced and unresectable, or metastatic NSCLC.
- Histologically or cytologically confirmed, either squamous or non-squamous NSCLC.
- Measurable disease as per RECIST 1.1
- Willingness to undergo bone marrow aspiration (BMA).
-
No more than one treatment regimen following an anti-PD-1 antibody containing treatment regimen prior to BMA collection.
a. Subjects may have BMA collected while on an anti-PD-1 antibody containing treatment regimen or while on a treatment regimen immediately following an anti-PD-1 antibody containing treatment regimen.
- BMA may be collected while on an anti-PD-1 antibody containing treatment regimen or while on a treatment regimen immediately following an anti-PD-1 antibody containing treatment regimen. However, the subjects must have radiographic evidence of disease progression prior to lymphodepletion.
- ≥ 21 days have lapsed since last cytotoxic chemotherapy treatment prior to collection of the BMA.
- Previous treatment with the appropriate targeted therapy if the subject has known EGFR/ALK/ROS1 rearrangements.
- Willingness to provide a fresh tumor biopsy during Screening Period or formalin-fixed, paraffin-embedded tissue collected at the time of most recent relapse. Note: Archival tissue regardless of biopsy date may be considered.
- Adequate renal, hepatic and bone marrow function defined as total bilirubin </= 1.5 x ULN (except for subjects with Gilbert's disease ≤ 3.0 x ULN with direct bilirubin </= 1.5 x ULN ). Aminotransferase (AST) / Alanine Aminotransferase (ALT) </= 3.0 X ULN (subjects with liver involvement will be allowed </= 5.0 X ULN). Serum creatinine </= 1.5 x ULN; if serum creatinine is 1.5 to 2.0 × ULN, then the creatinine clearance (calculated using the Cockcroft-Gault formula or measured) must be ≥ 40 mL/min. Lymphocyte >/= 0.7 x 10^9/L. ANC >/= 1.5 x 10^9/L. Platelets >/= 100 × 10^9/L. WBC >/= 2.0 ×10^9/L. Hemoglobin > 9.0 g/dL.
- Women of childbearing potential and male subjects (even if they are surgically sterilized or had a vasectomy) and their partners must agree to abstain or to use an effective form of birth control during the study for at least 6 months following administration of the last dose of lymphodepletion or for at least 5 months following the last dose of nivolumab for females and 7 months for males, whichever is longer. In addition, male subjects must not donate sperm during this period.
- Capable of giving and has provided a signed ICF, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
- Insufficient activation/expansion of T cells or other problems with the subject's MILs™ - NSCLC product which would prohibit administration.
- Major surgical procedure within 7 days of the first dose of lymphodepletion treatment.
- Prior malignancy active within the previous 3 years from date of BMA collection except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- Subjects with symptomatic uncontrolled brain metastases requiring treatment with steroids or anti-seizure medications within 28 days prior to the BMA are excluded. However, participants with brain metastases that have been previously treated and are stable on subsequent scan(s) are allowed and subjects with untreated possible brain metastases that are new at the time of screening and are < 1 cm and asymptomatic are allowed. Subjects with asymptomatic untreated CNS disease may undergo BMA prior to treatment of such disease.
- Infection requiring treatment with intravenous antibiotics, antifungal, or antiviral agents within 7 days prior to the BMA.
- Presence of an autoimmune disease requiring active systemic treatment.
- Clinically significant, uncontrolled cardiovascular disease, including congestive heart failure Grade III or IV according to the New York Heart Association classification, myocardial infarction or unstable angina within the previous 6 months prior to BMA collection.
- Known diagnosis of human immunodeficiency virus (HIV) or active viral hepatitis.
- Administration of neutrophil growth factor support within 14 days prior to the BMA.
- Use of systemic corticosteroids (glucocorticoids) for greater than one day within 28 days prior to the BMA.
- Planned use of systemic corticosteroids (glucocorticoids) for greater than one day within 28 days prior to MILs™ - NSCLC administration.
- Prior radiation to both sides of the pelvis. Prior radiation to one side of the pelvis is permitted as long as the other side of the pelvis.
- Subjects with history of life-threatening toxicity related to prior immune therapy except those that are unlikely to re-occur with standard countermeasures.
- Receipt of live attenuated vaccine within 30 days of planned Day 0.
- History of allergy or hypersensitivity to MILs™-NSCLC, cyclophosphamide, fludarabine, nivolumab, tadalafil or their components.
- Pregnant or lactating females.
- Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the subject or impair the assessment of study results.
- Unwilling or unable to comply with the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04069936
United States, California | |
City of Hope | |
Duarte, California, United States, 91010 | |
University of California - Los Angeles | |
Los Angeles, California, United States, 90095 | |
United States, Florida | |
Moffitt Cancer Center | |
Tampa, Florida, United States, 33612 | |
United States, Georgia | |
Emory University | |
Atlanta, Georgia, United States, 30322 | |
United States, Michigan | |
Karmanos Cancer Center | |
Detroit, Michigan, United States, 48201 | |
United States, Missouri | |
Washington University | |
Saint Louis, Missouri, United States, 63110 | |
United States, Nebraska | |
University of Nebraska Medical Center | |
Omaha, Nebraska, United States, 68198 | |
United States, Ohio | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
Fox Chase Cancer Center | |
Philadelphia, Pennsylvania, United States, 19111 | |
United States, Tennessee | |
Sarah Cannon Research Institute | |
Nashville, Tennessee, United States, 37203 |
Responsible Party: | WindMIL Therapeutics |
ClinicalTrials.gov Identifier: | NCT04069936 |
Other Study ID Numbers: |
CLN-P18001 |
First Posted: | August 28, 2019 Key Record Dates |
Last Update Posted: | June 18, 2021 |
Last Verified: | June 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
metastatic locally advanced lung cancer non-small cell lung cancer unresectable |
NSCLC cell therapy autologous cell therapy adoptive cell therapy |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Nivolumab |
Tadalafil Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Urological Agents |